These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 16503875)
1. Endocannabinoid receptor antagonists and other emerging pharma-cological strategies for weight reduction. Gadde KM Curr Drug Targets Cardiovasc Haematol Disord; 2005 Dec; 5(6):549-56. PubMed ID: 16503875 [TBL] [Abstract][Full Text] [Related]
2. Rimonabant in obese patients with type 2 diabetes. Randall MD; Kendall DA; Bennett AJ; O'Sullivan SE Lancet; 2007 Feb; 369(9561):555. PubMed ID: 17307094 [No Abstract] [Full Text] [Related]
3. [Pharmacological therapy of obesity]. Pagotto U; Vanuzzo D; Vicennati V; Pasquali R G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755 [TBL] [Abstract][Full Text] [Related]
4. Rimonabant: new data and emerging experience. Wright SM; Dikkers C; Aronne LJ Curr Atheroscler Rep; 2008 Feb; 10(1):71-8. PubMed ID: 18366988 [TBL] [Abstract][Full Text] [Related]
5. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. Després JP; Golay A; Sjöström L; N Engl J Med; 2005 Nov; 353(20):2121-34. PubMed ID: 16291982 [TBL] [Abstract][Full Text] [Related]
6. The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use. Xie S; Furjanic MA; Ferrara JJ; McAndrew NR; Ardino EL; Ngondara A; Bernstein Y; Thomas KJ; Kim E; Walker JM; Nagar S; Ward SJ; Raffa RB J Clin Pharm Ther; 2007 Jun; 32(3):209-31. PubMed ID: 17489873 [TBL] [Abstract][Full Text] [Related]
7. Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study results. Ruilope LM; Després JP; Scheen A; Pi-Sunyer X; Mancia G; Zanchetti A; Van Gaal L J Hypertens; 2008 Feb; 26(2):357-67. PubMed ID: 18192851 [TBL] [Abstract][Full Text] [Related]
8. Reducing cardiometabolic risk through selective antagonism of CB1 receptors. Van Gaal L Clin Cornerstone; 2007; 8 Suppl 6():S24-9. PubMed ID: 17948364 [TBL] [Abstract][Full Text] [Related]